Compare MGF & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MGF | ANIX |
|---|---|---|
| Founded | 1987 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.2M | 88.8M |
| IPO Year | N/A | 2013 |
| Metric | MGF | ANIX |
|---|---|---|
| Price | $2.85 | $2.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | 98.1K | ★ 99.1K |
| Earning Date | 01-01-0001 | 05-27-2026 |
| Dividend Yield | ★ 7.64% | N/A |
| EPS Growth | N/A | ★ 12.82 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $210,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.82 | $2.44 |
| 52 Week High | $3.14 | $5.46 |
| Indicator | MGF | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | 39.60 | 41.38 |
| Support Level | N/A | $2.65 |
| Resistance Level | $2.94 | $3.12 |
| Average True Range (ATR) | 0.04 | 0.12 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 25.00 | 21.48 |
MFS Government Markets Income Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to seek high current income. The fund invests a majority of the net assets, including borrowings for investment purposes, in U.S. and foreign government securities. The company invest various sectors like U.S. Treasury Securities, Mortgage-Backed Securities, Investment Grade Corporates, Municipal Bonds, Non-U.S. Government Bonds, etc, out of which maximum revenue is gained from U.S. Treasury Securities.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.